160 related articles for article (PubMed ID: 25142126)
1. Cytidine deamination and cccDNA degradation: A new approach for curing HBV?
Ding S; Robek MD
Hepatology; 2014 Dec; 60(6):2118-21. PubMed ID: 25142126
[No Abstract] [Full Text] [Related]
2. Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".
Xia Y; Lucifora J; Reisinger F; Heikenwalder M; Protzer U
Science; 2014 Jun; 344(6189):1237. PubMed ID: 24926011
[TBL] [Abstract][Full Text] [Related]
3. Virology. Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA".
Chisari FV; Mason WS; Seeger C
Science; 2014 Jun; 344(6189):1237. PubMed ID: 24926010
[TBL] [Abstract][Full Text] [Related]
4. Virology. Getting rid of a persistent troublemaker to cure hepatitis.
Shlomai A; Rice CM
Science; 2014 Mar; 343(6176):1212-3. PubMed ID: 24626921
[No Abstract] [Full Text] [Related]
5. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.
Lucifora J; Xia Y; Reisinger F; Zhang K; Stadler D; Cheng X; Sprinzl MF; Koppensteiner H; Makowska Z; Volz T; Remouchamps C; Chou WM; Thasler WE; Hüser N; Durantel D; Liang TJ; Münk C; Heim MH; Browning JL; Dejardin E; Dandri M; Schindler M; Heikenwalder M; Protzer U
Science; 2014 Mar; 343(6176):1221-8. PubMed ID: 24557838
[TBL] [Abstract][Full Text] [Related]
6. Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes.
Bockmann JH; Stadler D; Xia Y; Ko C; Wettengel JM; Schulze Zur Wiesch J; Dandri M; Protzer U
J Infect Dis; 2019 Jul; 220(4):567-577. PubMed ID: 30923817
[TBL] [Abstract][Full Text] [Related]
7. TGF-β triggers HBV cccDNA degradation through AID-dependent deamination.
Qiao Y; Han X; Guan G; Wu N; Sun J; Pak V; Liang G
FEBS Lett; 2016 Feb; 590(3):419-27. PubMed ID: 26867650
[TBL] [Abstract][Full Text] [Related]
8. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
[TBL] [Abstract][Full Text] [Related]
10. Formation of covalently closed circular DNA in Hep38.7-Tet cells, a tetracycline inducible hepatitis B virus expression cell line.
Ogura N; Watashi K; Noguchi T; Wakita T
Biochem Biophys Res Commun; 2014 Sep; 452(3):315-21. PubMed ID: 25150444
[TBL] [Abstract][Full Text] [Related]
11. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
13. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNA-bound histone acetylation.
Wei ZQ; Zhang YH; Ke CZ; Chen HX; Ren P; He YL; Hu P; Ma DQ; Luo J; Meng ZJ
World J Gastroenterol; 2017 Sep; 23(34):6252-6260. PubMed ID: 28974891
[TBL] [Abstract][Full Text] [Related]
14. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
Lu HY; Zhuang LW; Yu YY; Si CW; Li J
Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
[TBL] [Abstract][Full Text] [Related]
15. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
16. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA.
Liu C; Cai D; Zhang L; Tang W; Yan R; Guo H; Chen X
Antiviral Res; 2016 Oct; 134():97-107. PubMed ID: 27591143
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection.
Meier MA; Suslov A; Ketterer S; Heim MH; Wieland SF
J Viral Hepat; 2017 Aug; 24(8):662-671. PubMed ID: 28182305
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes.
Köck J; Baumert TF; Delaney WE; Blum HE; von Weizsäcker F
Hepatology; 2003 Dec; 38(6):1410-8. PubMed ID: 14647052
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation.
Tanaka T; Okuyama-Dobashi K; Murakami S; Chen W; Okamoto T; Ueda K; Hosoya T; Matsuura Y; Ryo A; Tanaka Y; Hagiwara M; Moriishi K
Antiviral Res; 2016 Sep; 133():156-64. PubMed ID: 27515132
[TBL] [Abstract][Full Text] [Related]
20. Concerted action of activation-induced cytidine deaminase and uracil-DNA glycosylase reduces covalently closed circular DNA of duck hepatitis B virus.
Chowdhury S; Kitamura K; Simadu M; Koura M; Muramatsu M
FEBS Lett; 2013 Sep; 587(18):3148-52. PubMed ID: 23954625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
